CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-28 | Lynx1 Capital Management LP 10% owner | Purchase | +165,667 | $8.40 | $1.4M | 8,963,500 |
| 2025-10-17 | Lynx1 Capital Management LP 10% owner | Purchase | +32,217 | $7.84 | $253K | 8,797,833 |
| 2025-10-16 | Lynx1 Capital Management LP 10% owner | Purchase | +150,000 | $8.86 | $1.3M | 8,765,616 |
| 2025-10-15 | Lynx1 Capital Management LP 10% owner | Purchase | +51,500 | $7.94 | $409K | 8,615,616 |
| 2025-10-14 | Lynx1 Capital Management LP 10% owner | Purchase | +15,032 | $7.59 | $114K | 8,564,116 |
| 2025-10-10 | Lynx1 Capital Management LP 10% owner | Purchase | +277,298 | $7.36 | $2.0M | 8,549,084 |
| 2025-10-09 | Lynx1 Capital Management LP 10% owner | Purchase | +626,043 | $6.70 | $4.2M | 8,271,786 |
| 2025-10-08 | Lynx1 Capital Management LP 10% owner | Purchase | +556,300 | $6.46 | $3.6M | 7,645,743 |
| 2025-08-07 | Allen Andrew R Director | Grant or award · Stock Option (Right to Buy) | +79,456 | 79,456 | ||
| 2025-08-07 | Doyle Mittie Director | Grant or award · Stock Option (Right to Buy) | +79,456 | 79,456 | ||
| 2025-06-12 | Ryan David P. Director | Grant or award · Stock Option (Right to Buy) | +38,513 | 38,513 | ||
| 2025-06-12 | Rosenberg Anthony Director | Grant or award · Stock Option (Right to Buy) | +38,513 | 38,513 | ||
| 2025-06-12 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +38,513 | 38,513 | ||
| 2025-06-12 | Meek David D. Director | Grant or award · Stock Option (Right to Buy) | +38,513 | 38,513 | ||
| 2025-06-12 | Martin Anne-Marie Director | Grant or award · Stock Option (Right to Buy) | +38,513 | 38,513 | ||
| 2025-02-25 | Jones Jeffrey Alan Chief Medical Officer | Sale | −4,895 | $8.53 | $42K | 174,164 |
| 2025-02-25 | Michaelson Jennifer Chief Scientific Officer | Sale | −3,756 | $8.53 | $32K | 142,004 |
| 2025-02-25 | AHMED NADIM President and CEO | Sale | −12,529 | $8.53 | $107K | 430,621 |
| 2025-02-25 | SUMER JACQUELYN L Chief Legal Officer | Sale | −3,756 | $8.53 | $32K | 136,895 |
| 2025-02-19 | Michaelson Jennifer Chief Scientific Officer | Grant or award | +50,000 | 145,760 |
Page 4 of 23 · 446 trades